Licensing Deal Benchmarks
PoS-adjusted, structure-decomposed benchmarks.
Benchmarks for pharma licensing deals — by phase, modality, TA, structure and PoS-adjusted real value.
"Where does our deal price within the credible band?"
Headline deal value misleads. Decompose into upfront / milestones / royalties; PoS-adjust milestones; segment by phase, modality and geo rights.
Licensing deal benchmarks are useful only PoS-adjusted and structure-decomposed. Headline deal values misleadingly inflate by 30–50% over real economics.
What we’re seeing in the data.
PoS-adjusted real value 30–50% below headline
Standard discount.
Phase 2 is the inflection
Upfronts spike sharply post-P2 proof.
Geo splits common
US-only, ex-US, Asia rights.
How to think about it.
-
01
Decompose value
Upfront / dev / reg / sales milestones / royalties.
-
02
PoS-adjust milestones
Phase- and TA-specific.
-
03
Benchmark vs comp set
TA × phase × modality × geo.
-
04
Score structural features
Options, opt-outs, cost-share.
What separates a good answer from a defensible one.
Triangulate.
Hot TAs price above comp.
Increasing in importance.
Where the signal comes from.
Common questions.
Fair upfront?
Highly TA + phase specific. Never use a flat benchmark.
Confidentiality?
Triangulate disclosed bands across comparable deals.
Want this answered on your data?
We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.
Talk to a strategist